SIGLEC1 and gastric cancer: These studies reported the association between CD169+ macrophages and CD8+ T cells in patients with gastric cancer, hepatocellular carcinoma, colorectal carcinoma, esophageal cancer, bladder cancer, endometrial carcinoma, malignant melanoma, breast cancer, or oral squamous cell carcinoma.